YZ9 1g | ≥98%
CSNpharm
YZ9 is a PFKFB3 inhibitor with IC50 of 0.183 μM, also inhibits F-6-P with Ki of 0.094 μM.
More Information Supplier PageYZ9
Search Results
YZ9 250mg | ≥98%
CSNpharm
YZ9 is a PFKFB3 inhibitor with IC50 of 0.183 μM, also inhibits F-6-P with Ki of 0.094 μM.
More Information Supplier PageYZ9
β-NADP 50mg | ≥98%
CSNpharm
β-NADP is an electron acceptor which acts as a key cofactor for electron transfer in the metabolism. Its oxidized form and reduced form are NADP+ and NADPH.
More Information Supplier Pageβ-NADP
(R)-GNE-140 10mg | ≥99%
CSNpharm
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor with IC50s of 3 nM and 5 nM for LDHA and LDHB respectively.
More Information Supplier Page(R)-GNE-140
(R)-GNE-140 100mg | ≥99%
CSNpharm
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor with IC50s of 3 nM and 5 nM for LDHA and LDHB respectively.
More Information Supplier Page(R)-GNE-140
(R)-GNE-140 50mg | ≥99%
CSNpharm
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor with IC50s of 3 nM and 5 nM for LDHA and LDHB respectively.
More Information Supplier Page(R)-GNE-140
MMPEP 5mg | ≥99%
CSNpharm
MPEP HCl is both a selective non-competitive mGlu5 receptor antagonist with IC50 value of 36 nM, and a mGlu4 receptor positive allosteric modulator.
More Information Supplier PageMMPEP
MMPEP 10mg | ≥99%
CSNpharm
MPEP HCl is both a selective non-competitive mGlu5 receptor antagonist with IC50 value of 36 nM, and a mGlu4 receptor positive allosteric modulator.
More Information Supplier PageMMPEP
XRK3F2 10mg | ≥99%
CSNpharm
XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.
More Information Supplier PageXRK3F2
XRK3F2 100mg | ≥99%
CSNpharm
XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.
More Information Supplier PageXRK3F2